13F filings
OrbiMed
$5.0B to $5.4B. Includes price moves and buying or selling; not the fund's return.
Free on iOS and Android.
Sector mix of the disclosed holdings
by disclosed valueThe grey slice is holdings without a sector on record, among them calls and puts worth 2.2% of the disclosed value, which get no sector because a put is a position against a company.
Largest holdings
50 largest of 128 positions| Holding | Type | Value | Shares | % of 13F value |
|---|---|---|---|---|
| EWTXEdgewise Therapeutics | Shares | $630.5M | 15,518,492 | 11.7% |
| ELVNEnliven Therapeutics | Shares | $343.9M | 6,776,632 | 6.4% |
| LLYEli Lilly | Shares | $309.3M | 257,900 | 5.8% |
| MBXMBX Biosciences | Shares | $189.3M | 3,428,736 | 3.5% |
| SINXSinovac Biotech | Shares | $184.5M | 2,718,735 | 3.4% |
| AZNAstraZeneca | Shares | $171.1M | 915,700 | 3.2% |
| GPCRStructure Therapeutics | Shares | $118.6M | 2,209,400 | 2.2% |
| SIONSionna Therapeutics | Shares | $112.4M | 2,555,877 | 2.1% |
| CRVSCorvus Pharmaceuticals | Shares | $107.0M | 7,165,006 | 2.0% |
| AVBPArriVent BioPharma | Shares | $105.2M | 3,027,328 | 2.0% |
| GHGuardant Health | Shares | $87.6M | 583,700 | 1.6% |
| ARGXargenx SE | Shares | $86.2M | 92,880 | 1.6% |
| MRKMerck | Shares | $85.2M | 663,400 | 1.6% |
| QUREuniQure | Shares | $83.3M | 1,807,486 | 1.6% |
| PRAXPraxis Precision Medicines | Shares | $77.0M | 230,100 | 1.4% |
| EWEdwards Lifesciences | Shares | $75.5M | 834,900 | 1.4% |
| PRLDPrelude Therapeutics | Shares | $73.2M | 13,724,571 | 1.4% |
| ABVXAbivax | Shares | $72.8M | 546,522 | 1.4% |
| DYNDyne Therapeutics | Shares | $71.9M | 3,235,684 | 1.3% |
| NTRANatera | Shares | $71.1M | 262,000 | 1.3% |
| CGONCG Oncology | Shares | $69.1M | 972,800 | 1.3% |
| UNHUnitedHealth Group | Shares | $67.0M | 161,100 | 1.2% |
| SPRYARS Pharmaceuticals | Shares | $66.4M | 8,288,510 | 1.2% |
| ASNDAscendis Pharma A/S | Shares | $65.2M | 244,456 | 1.2% |
| HUMHumana | Shares | $65.2M | 164,100 | 1.2% |
| COGTCogent Biosciences | Shares | $65.1M | 1,681,300 | 1.2% |
| BSXBoston Scientific | Shares | $63.3M | 1,483,200 | 1.2% |
| ISRGIntuitive Surgical | Shares | $62.8M | 157,900 | 1.2% |
| MLYSMineralys Therapeutics | Shares | $56.9M | 2,110,300 | 1.1% |
| ODTXOdyssey Therapeutics | Shares | $56.2M | 3,001,198 | 1.0% |
| XENEXenon Pharmaceuticals | Shares | $53.9M | 892,471 | 1.0% |
| ARQTArcutis Biotherapeutics | Shares | $53.5M | 2,042,000 | 1.0% |
| BMYBristol-Myers Squibb | Shares | $53.3M | 925,000 | 1.0% |
| QTTBQ32 Bio | Shares | $52.6M | 4,127,987 | 1.0% |
| SYKStryker | Shares | $50.1M | 159,100 | 0.9% |
| CAICaris Life Sciences | Shares | $50.0M | 2,806,811 | 0.9% |
| XBIState Street SPDR S&P Biotech ETF | Put | $47.5M | 300,000 | 0.9% |
| TMOThermo Fisher Scientific | Shares | $45.5M | 90,700 | 0.8% |
| PVLAPalvella Therapeutics | Shares | $44.7M | 292,360 | 0.8% |
| ELVElevance Health | Shares | $44.4M | 114,700 | 0.8% |
| STTKShattuck Labs | Shares | $43.8M | 6,306,127 | 0.8% |
| UPBUpstream Bio | Shares | $39.4M | 5,693,589 | 0.7% |
| CRNXCrinetics Pharmaceuticals | Shares | $37.4M | 999,000 | 0.7% |
| RYTMRhythm Pharmaceuticals | Shares | $35.9M | 322,900 | 0.7% |
| SNDXSyndax Pharmaceuticals | Shares | $33.7M | 1,542,000 | 0.6% |
| FBRXForte Biosciences | Shares | $33.5M | 1,577,705 | 0.6% |
| CMPXCompass Therapeutics | Shares | $33.3M | 15,219,994 | 0.6% |
| NKTRNektar Therapeutics | Shares | $32.5M | 465,346 | 0.6% |
| KRYSKrystal Biotech | Shares | $30.9M | 83,200 | 0.6% |
| AXSMAxsome Therapeutics | Shares | $28.8M | 117,578 | 0.5% |
% of 13F value is the position's value against the whole disclosed 13F value, so the rows shown here do not sum to 100% unless every position is listed. Calls and puts are shown as filed: most filers give Value as the notional value of the shares underneath, not money invested, but some give the premium paid, and some count contracts rather than shares.
GetSignal pushes each new 13F to your phone as it is filed, with the positions that changed and the companies behind them. Free on iOS and Android.
What OrbiMed bought and sold in Q2 2026
15 largest moves| Holding | Move | Share change | Est. amount moved | Value after |
|---|---|---|---|---|
| MDXHMDxHealth | Exited call | -100% | -$285.9M | $0 |
| RCELAvita Medical | Exited call | -100% | -$154.4M | $0 |
| UNHUnitedHealth Group | New | new | +$67.0M | $67.0M |
| HUMHumana | New | new | +$65.2M | $65.2M |
| ELVNEnliven Therapeutics | Trimmed | -14.9% | -$60.0M | $343.9M |
| ODTXOdyssey Therapeutics | New | new | +$56.2M | $56.2M |
| PFEPfizer | Exited | -100% | -$54.7M | $0 |
| ARQTArcutis Biotherapeutics | New | new | +$53.5M | $53.5M |
| COGTCogent Biosciences | Added | +422.0% | +$52.6M | $65.1M |
| IRONDisc Medicine | Trimmed | -66.5% | -$51.9M | $26.2M |
| DHRDanaher | Exited | -100% | -$50.4M | $0 |
| XBIState Street SPDR S&P Biotech ETF | New put | new | +$47.5M | $47.5M |
| AZNAstraZeneca | Added | +36.6% | +$45.9M | $171.1M |
| SIONSionna Therapeutics | Trimmed | -27.6% | -$42.9M | $112.4M |
| RCELAvita Medical | Exited | -100% | -$42.5M | $0 |
A change is this filing measured against the one before it. Est. amount moved is the shares added or sold, priced at the Jun 30, 2026 close. An estimate: a 13F gives no trade prices or dates. For a sold-out position, its value at the previous quarter end. A put gains when the stock falls; a call gains when it rises. Option values are as filed, which for most filers is the notional value of the shares underneath.
Questions
What does OrbiMed hold?
OrbiMed disclosed 128 positions worth $5.4B in the Q2 2026 13F filing. The largest is EWTX at 11.7% of the disclosed value. A 13F lists US-listed stock and options on it; short sales and cash are not in it.
What did OrbiMed buy and sell last quarter?
Comparing the Q2 2026 filing with the quarter before, the largest moves were selling out of a call on MDXH, selling out of a call on RCEL, opening a position in UNH and opening a position in HUM. Changes are measured against the previous filing, not against trades, because a 13F does not disclose trades.
How current is this?
This is the Q2 2026 filing, covering positions held on Jun 30, 2026 and filed with the SEC on Aug 14, 2026. A 13F is due 45 days after the quarter ends, so the most recent filing is always at least six weeks behind the market, and the manager may have changed the book since.
How to read a 13F
WHAT THE FILING COVERS
Positions are as disclosed to the SEC on Form 13F and are not investment advice. How this data is sourced, and what it cannot tell you, is on the methodology page. How the filing itself works is explained in our guide to Form 13F.
Checked for newer filings on Oct 26, 2026.